Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track

Feb 13

Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.

The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.

These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163537536"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163537536\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163537536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163537536","market":"nz","top_or_hot":-1,"title":"Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report","media":"Stock Track","content":"<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1163537536","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163537536","pubTimestamp":1770993370,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"个股追踪|Vertex Pharmaceuticals财报后多位分析师上调评级盘中飙升5.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}